Release Summary

Alexion announced that researchers presented 24-week results from an ongoing open-label, Phase I/II trial of intravenous SBC-103 (rhNAGLU enzyme), an investigational ERT, in children with MPS IIIB.

Alexion Pharmaceuticals, Inc.